Intellectual Property—26 Issued or Allowed Patents

Glycotest IP strategy is to enable multiple layers of protection for key liver disease tests through multiple patent families prosecuted in commercially important jurisdictions—individual biomarkers; assay technology; panels and algorithms


• HCC Panel patent application (PCT/US2017/018040 and Taiwan 106106107)

o Panels and algorithms, including the HCC Panel

o Issued US (11,408,888), European (3419646), Japanese (7026390), Taiwan (I769149), Mexican (398169) and allowed Chinese patents

•  PCT/US2010/044307

o Engineered lectins and methods for fucosylated biomarker assays

o Issued European (2462240) and Chinese (ZL201080044720.8) patents

•  PCT/US2006/017478

o Methods for diagnosing liver disease using fucosylated biomarkers

o Issued US (7,776,550; 8,183,000; 10,082,512; 10,823,740), European (3056905; 3578985), Australian (2006244398; 2012247075; 2015275300), Japanese (5964769; 6184935; 6553142), Canadian (2607285; 3021449), and Hong Kong (HK1228005; HK40017435) patents

•  US2009/0253180

o Methods for diagnosing liver disease using fucosylated LRAGG

o Issued US patents (9,110,078; 10,180,436)

•  Trade Secrets

o Fucosylated biomarker assay manufacturing technology

o Fucosylated biomarker assay methods


• Exploits unique disease signal chemistry (glycoprotein fucosylation) present in liver cancers and fibrosis-cirrhosis but absent in healthy individuals Incorporated into highly promising biomarker panels

• Focused on the detection of potentially curable early-stage disease

• May outperform currently available serum biomarkers, such as AFP

• Targeting the worldwide liver cancer threat that kills more than 700,000 people annually and is the fastest growing cause of cancer death in the US


A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

Intellectual Property | Glycotest Diagnostics